retatrutide

News

Lilly's triple agonist retatrutide passes diabetes test

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

News

Lilly names Pennsylvania site for its latest US facility

Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US - a $3.5bn facility in Pennsylvania.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

Lilly's obesity triple pulls off 29% weight loss in trial

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.

News

Lilly ends ADA on a high as obesity triple data pops

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru

Lilly's triple agonist retatrutide passes diabetes test

Lilly names Pennsylvania site for its latest US facility

11 high-impact drugs to look out for in 2026

Lilly's obesity triple pulls off 29% weight loss in trial

Lilly ends ADA on a high as obesity triple data pops

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

retatrutide

Editor's Picks